Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2Sarcoma 1Rhabdomyosarcoma 1Neoplasms 1Medulloblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × LY2940680 × Clear all
NCT01226485 2019-09-13

A Study in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
84 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01919398 2019-09-11

A Study of LY2940680 in Japanese Participants With Advanced Cancers

Eli Lilly and Company

Phase 1 Completed
19 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡